Claims:

1. Use of a therapeutically effective amount of an acellular allogenic preparation (acellular human umbilical cord plasma with exosomes (UCF) or exosomes only (UCF-E) from human umbilical cord plasma) wherein the acellular allogenic exosome preparation (UCF or UCF-E) is derived from human umbilical cord blood, in the manufacture of a medicament for treating or improving a symptom of a neuronal injury in a subject, wherein the neuronal injury is ischemic brain injury, haemorrhagic brain injury, or traumatic brain injury, and wherein the medicament is first administered from 3 to 90 days after the neuronal injury.

2. The use of claim 1, wherein the medicament is first administered 7 to 10 days after the neuronal injury.

3. The use of claim 1 or 2, wherein the medicament is administered intrathecally.

4. The use of any one of claims 1 to 3, wherein the medicament is administered periodically to the subject, preferably every week, every two weeks, every three weeks, every month, more preferably daily, every 5 days, every 10 days, every 15 days, every 20 days, every 25 days, about every 30 days, or a combination thereof.

5. The use of any one of claims 1 to 4, wherein the ischemic brain injury or haemorrhagic brain injury is a stroke.

6. The use of any one of claims 1 to 5, wherein the medicament does not comprise an immunosuppressive agent.

7. The use of any one of claims 1 to 6, wherein

the acellular human umbilical cord plasma with exosomes (UCF) is characterized by a level of one or more of GM-CSF, HGF, MIP-1b (CCL4) and PDGF-bb that is at least 20% higher than is found in normal adult serum; and/or

the acellular allogenic preparation with exosomes (UCF) and exosomes only (UCF-E) are characterized by a level of IP-10 (CxCL10) that is at least 60% of the level found in normal adult serum.

8. The use of any one of claims 1 to 7, wherein exosomes in the allogenic preparation containing exosomes (UCF or UCF-E) comprise at least one of CD63 and TSG101 and lack lipoprotein markers APOB and APOE.

9. The use of any one of claims 1 to 8, wherein the acellular allogenic preparation containing exosomes (UCF and UCF-E) comprises exosomes with a mean, median or mode particle size of about 30-150 nm.

10. The use of any one of claims 1 to 9, wherein the medicament is formulated for administering the acellular allogenic preparation with exosomes (UCF and UCF-E) a total of two, three, four, five, six, seven, eight, nine or ten times.

11. The use of any one of claims 1 to 10, wherein the symptom is selected from dystonia, aphasia, infarct size, infarct volume, inflammation, loss of white matter, loss of grey matter, apoptotic cells in the peri-infarct region, systemic inflammation, inflammation in the infarct or peri-infarct region, and CD16/CD32 positive cells in the peri-infarct region.

12. The use of any one of claims 1 to 11, wherein the medicament comprises at least one additional therapeutic agent.

13. The use of claim 12, wherein the additional therapeutic agent is an anti-inflammatory agent, steroid, dipyridamole, astaxanthin, dabigatran, losartan, nimodipine, policosanol, rivaroxaban, ticlopidine, mannitol, intracarotid arterial hyperosmolar mannitol (ICAHM), RMP-7, or regadenoson.

14. Use of an acellular allogenic preparation with exosomes (UCF or UCF-E), wherein the acellular allogenic preparation (UCF or UCF-E) is derived from pooled human umbilical cord blood, in the manufacture of a medicament for improving a mRS score or NIHSS score

of a subject with an ischemic brain injury and wherein the medicament is first administered from 3 to 90 days after the ischemic brain injury.

15. The use of claim 14, wherein the medicament is first administered 7 to 10 days after the ischemic brain injury.

16. The use of claim 14 or 15, wherein the medicament does not comprise an immunosuppressive agent.

17. The use of any one of claims 14 to 16, wherein the allogenic preparation with exosomes (UCF or UCF-E) is administered periodically to the subject, preferably every week, every two weeks, every three weeks, every month, more preferably daily, every 5 days, every 10 days, every 15 days, every 20 days, every 25 days, about every 30 days, or a combination thereof.

18. The use of any one of claims 14 to 17, wherein the medicament is formulated for administering the acellular allogenic preparation with exosomes (UCF or UCF-E) a total of two, three, four, five, six, seven, eight, nine or ten times.

19. The use of any one of claims 1 to 18, wherein the UCF or UCF-E is derived from blood of a single umbilical cord, or pooled blood from multiple umbilical cords.

20. The use of claim 19 wherein the pooled blood is from umbilical cords with the same blood group or from umbilical cords with different blood groups.